Suppression of hypothalamic–pituitary–gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models
Clinical and Experimental Pharmacology and Physiology · 2023
DOI: 10.1111/1440-1681.13817 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2023. Verfasst von Motohiro Tezuka und 8 weiteren Autor:innen. Beteiligte Einrichtung: Central Research Laboratories, Kissei Pharmaceutical Co., Ltd., Azumino, Japan. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Prostatic Hyperplasia, Hypothalamo-Hypophyseal System. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
The hypothalamic–pituitary–gonadal (HPG) axis is an important regulatory mechanism involved primarily in the development and regulation of the reproductive systems. The suppression of the HPG axis by gonadotropin‐releasing hormone (GnRH) analogues is expected to be effective for the treatment of sex hormone‐dependent diseases, such as endometriosis, uterine fibroid, prostate cancer, benign prostatic hyperplasia (BPH) and polycystic ovary syndrome (PCOS). Despite the established involvement of GnRH signalling in these disorders, the therapeutic efficacy of small molecular GnRH antagonists for BPH and PCOS has not been adequately evaluated in non‐clinical studies. Therefore, the purpose of the present study was to evaluate the potential of linzagolix, a small molecular GnRH antagonist, as a potential new treatment option for BPH and PCOS. Dogs and rats exhibiting normal prostates and dogs diagnosed with prostatic hyperplasia were used to evaluate the effects of linzagolix in BPH. The effects of linzagolix were also examined in a rat model of PCOS induced by repeated administration of letrozole, an aromatase inhibitor. Linzagolix reduced serum luteinizing hormone and testosterone levels in male rats and normal or BPH model dogs and suppressed prostate weight without testosterone depletion, suggesting the existence of an optimal therapeutic testosterone level for BPH treatment. In a PCOS rat model, linzagolix improved both insulin resistance and ovarian dysfunction. Treatment with linzagolix decreased follicle‐stimulating hormone levels, but did not alter serum luteinizing hormone and testosterone levels. These results indicate that linzagolix may provide a new treatment option for GnRH‐related disorders, such as BPH and PCOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Research Laboratories, Kissei Pharmaceutical Co., Ltd., Azumino, Japan.
- Safety Research Department, Kissei Pharmaceuticals Co., Ltd., Azumino, Japan.
Zitieren
APA
Tezuka, M., Yonekubo-Awaka, S., Tamai, Y., Tsuchioka, K., Kobayashi, K., Kuramochi, Y., Tatemichi, S., Nagasawa, T., & Kiguchi, S. (2023). Suppression of hypothalamic–pituitary–gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.13817
Vancouver
Tezuka M, Yonekubo-Awaka S, Tamai Y, Tsuchioka K, Kobayashi K, Kuramochi Y, et al. Suppression of hypothalamic–pituitary–gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models. Clinical and Experimental Pharmacology and Physiology. 2023. doi:10.1111/1440-1681.13817
BibTeX
@article{Tezuka2023,
author = {Tezuka, Motohiro and Yonekubo-Awaka, Saori and Tamai, Yasuaki and Tsuchioka, Kumi and Kobayashi, Kaoru and Kuramochi, Yu and Tatemichi, Satoshi and Nagasawa, Tatsuya and Kiguchi, Sumiyoshi},
title = {Suppression of hypothalamic–pituitary–gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2023},
doi = {10.1111/1440-1681.13817}
}
EUVIMED